Summary: In a 26-week, double-blind, Novo Nordisk-funded Phase IIIa trial of 1441 adults with type 2 diabetes inadequately controlled on metformin (75.2% from the China region), once-daily oral semaglutide at 3, 7 and 14 mg produced significantly greater reductions in HbA1c and body weight than oral sitagliptin 100 mg. The largest effects were dose-dependent (HbA1c treatment difference up to -1.0 percentage points and weight up to -3.3 kg at 14 mg), and gastrointestinal adverse events and treatment discontinuation were more frequent on the higher semaglutide doses.
PICO Summary
| Element | Detail |
|---|---|
| Population | 1441 adults (aged ≥18 years, ≥20 in Taiwan) with type 2 diabetes, HbA1c 53-91 mmol/mol, inadequately controlled on metformin; randomised, double-blind, double-dummy, active-controlled Phase IIIa trial at 90 sites across the China region (mainland China, Taiwan, Hong Kong) and five other countries; 75.2% from the China region. |
| Intervention | Once-daily oral semaglutide 3 mg (n=361), 7 mg (n=360) or 14 mg (n=361) for 26 weeks. |
| Comparison | Once-daily oral sitagliptin 100 mg (n=359) for 26 weeks. |
| Outcome | Primary endpoint, change in HbA1c at week 26: estimated treatment differences vs sitagliptin were -0.2 percentage points (95% CI -0.3, -0.1; -2 mmol/mol) for 3 mg, -0.7 (95% CI -0.8, -0.6; -8 mmol/mol) for 7 mg and -1.0 (95% CI -1.1, -0.8; -11 mmol/mol) for 14 mg, all significantly favouring semaglutide. Confirmatory secondary endpoint, body weight: ETDs vs sitagliptin were -0.9 kg (95% CI -1.4, -0.4), -2.3 kg (95% CI -2.8, -1.8) and -3.3 kg (95% CI -3.8, -2.8) for 3, 7 and 14 mg. Gastrointestinal adverse events were most frequent on semaglutide but mostly transient and mild to moderate; premature treatment discontinuation rose with dose (8.3%, 8.6% and 15.0% for 3, 7 and 14 mg vs 4.2% for sitagliptin). No ARR/NNT reported for a clinical endpoint. |
PIONEER 12: oral semaglutide vs sitagliptin
RCT · type 2 diabetes · 26 weeks
Oral semaglutide cut HbA1c and weight more than sitagliptin in a mostly Chinese, metformin-treated population, with dose-dependent benefit. Gastrointestinal intolerance and discontinuation rose at the 14 mg dose.
Expert Commentary
This trial supports a clear verdict: oral semaglutide was superior to sitagliptin for both glycaemic control and weight in a predominantly Chinese metformin-treated population, and the double-blind, double-dummy design with central randomisation lends the comparison good internal validity. The effect was dose-dependent and clinically meaningful at the top dose, where a treatment difference of about 1.0 percentage point in HbA1c and 3.3 kg in weight is the kind of separation that changes management. The headline weakness is the price of that efficacy: premature treatment discontinuation reached 15.0% on 14 mg against 4.2% on sitagliptin, a near fourfold difference driven largely by gastrointestinal intolerance, so the average benefit will not be realised in every patient who starts the drug. Two further caveats deserve weight. The trial was funded by the manufacturer, Novo Nordisk, with several authors employed by the sponsor, and the comparator was an active agent rather than placebo, which frames these as relative not absolute gains over no treatment. The 26-week horizon also says nothing about durability or cardiovascular and renal outcomes. Can I use this with my patients? Yes, for a metformin-treated adult of East Asian background who wants an oral agent with added weight benefit and can tolerate slow titration, with the caveat that intolerance at higher doses is common. Clinicians should titrate cautiously and counsel openly on gastrointestinal effects rather than defaulting to the maximum dose.
References
Ji L, Agesen RM, Bain SC, et al. Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial. Diabetologia. 2024;67(9):1800-1816. doi:10.1007/s00125-024-06133-4
